Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CHOLEDYL SA vs AEROLATE SR
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Choledyl SA (theophylline, sustained-release) is a methylxanthine that inhibits phosphodiesterase, increasing intracellular c AMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.
AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.
Treatment of symptoms and reversible airway obstruction associated with chronic asthma and other chronic lung diseases (e.g., emphysema, chronic bronchitis)
Treatment of symptoms and reversible airway obstruction associated with chronic asthma,Chronic obstructive pulmonary disease (COPD),Apnea of prematurity (off-label)
400 mg orally every 12 hours (sustained-release); maximum 800 mg every 12 hours.
400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.
Terminal elimination half-life: 7-9 hours in healthy adults; prolonged in hepatic cirrhosis (up to 30 hours), heart failure, COPD, and in neonates; shortened in smokers and cystic fibrosis.
Terminal elimination half-life 12 hours (range 10–15 h) in adults; prolonged in hepatic impairment (up to 24 h) and elderly.
Primarily hepatic via CYP1A2, with minor contributions from CYP2E1 and CYP3A4; exhibits nonlinear pharmacokinetics at higher concentrations.
Primarily hepatic via cytochrome P450 enzymes (CYP1A2, CYP2E1, and CYP3A4). Theophylline is metabolized to 1,3-dimethyluric acid, 1-methyluric acid, and 3-methylxanthine.
Renal: 90% as unchanged drug and metabolites (theophylline metabolites including 1,3-dimethyluric acid, 3-methylxanthine, and 1-methyluric acid). Biliary/fecal: <10%.
Renal: 60% as unchanged drug; biliary/fecal: 30% as metabolites; 10% as unchanged in feces.
55-60% bound, primarily to albumin.
55–65% bound to plasma proteins, primarily albumin.
0.45 L/kg (0.3-0.7 L/kg). Reflects distribution into total body water, with lower Vd in obese patients when adjusted for ideal body weight.
0.4–0.6 L/kg, indicating distribution into total body water.
Oral: 100% for choline theophyllinate (Choledyl) as it is completely absorbed; the sustained-action formulation (Choledyl SA) has equivalent bioavailability to immediate-release.
Oral: 90–100% for sustained-release formulation; food decreases rate but not extent (AUC unchanged).
GFR 50-80 m L/min: 50% of usual dose; GFR <50 m L/min: avoid use due to accumulation of choline and theophylline.
No dose adjustment required for renal impairment.
Child-Pugh A: 50% of usual dose; Child-Pugh B: 25% of usual dose; Child-Pugh C: contraindicated.
Use with caution in severe hepatic impairment (Child-Pugh class C); consider dose reduction by 50%.
Not recommended for use in children under 12 years due to lack of safety data.
Children 6-12 years: 200-400 mcg inhaled twice daily. Children over 12 years: same as adult dose.
Initiate at 400 mg every 12 hours; titrate slowly with monitoring of serum theophylline levels due to reduced clearance.
Start at lower end of dosing range (400 mcg twice daily) and titrate to response; monitor for systemic effects.
No FDA black box warning.
No FDA black box warning exists for this drug.
Theophylline has narrow therapeutic index; serum levels must be monitored to avoid toxicity (toxicity risk increases above 20 mcg/m L).,Concomitant use with other xanthines may potentiate toxicity.,Use with caution in patients with cardiovascular disease (e.g., arrhythmias), seizure disorders, hepatic impairment, or peptic ulcer disease.,Drug interactions: CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) increase theophylline levels; CYP1A2 inducers (e.g., phenytoin, rifampin) decrease levels.,Risk of hypokalemia and hypophosphatemia with high doses or prolonged use.
Theophylline has a narrow therapeutic index; serum levels must be monitored to avoid toxicity. Toxicity can include seizures, cardiac arrhythmias, and death. Caution in patients with heart failure, hepatic impairment, or those over 55 years. Risk of toxicity increased by concurrent medications such as cimetidine, fluoroquinolones, and macrolides.
Hypersensitivity to theophylline or any component of the formulation.,Acute myocardial infarction with bradycardia or tachyarrhythmias.,Active seizure disorder not controlled with anticonvulsant therapy.
Hypersensitivity to theophylline or any component of the formulation; active seizure disorder; untreated cardiac arrhythmias; severe hypertension; hyperthyroidism; peptic ulcer disease; caution with concurrent use of ephedrine or other sympathomimetics.
Avoid high-fat meals that may alter absorption. Caffeine (coffee, tea, cola, chocolate) potentiates adverse effects. Charcoal-broiled foods can increase theophylline metabolism.
High-fat meals may delay absorption. Avoid charcoal-grilled foods and large amounts of caffeine. Grapefruit juice may increase theophylline levels; limit intake.
FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, theophylline (active metabolite) caused fetal toxicity at high doses. First trimester: risk unknown; use only if benefit outweighs risk. Second/third trimester: possible fetal tachycardia and irritability; avoid near term due to potential neonatal apnea, jitteriness, and withdrawal symptoms.
Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypoglycemia, and reduced uterine contractility; avoid use near term due to potential for neonatal bradycardia and hypoglycemia.
Theophylline is excreted into breast milk with M/P ratio approximately 0.6-0.7. Infant may receive 1-10% of maternal dose. Monitor infant for irritability, insomnia, and tachycardia. Use caution; benefit should outweigh risk. Alternative agents may be preferred.
Salbutamol is excreted into breast milk in minimal amounts; estimated infant dose <2% of maternal weight-adjusted dose. No known adverse effects in nursing infants. M/P ratio not established. Use with caution.
Pregnancy may reduce theophylline clearance (especially third trimester) due to decreased hepatic metabolism and increased volume of distribution. Dose reduction may be needed; monitor levels and adjust to maintain therapeutic range. Postpartum clearance increases rapidly; adjust dose downward after delivery to avoid toxicity.
No dose adjustment required for inhaled salbutamol. Increased clearance in late pregnancy may necessitate higher doses for systemic effects; monitor clinical response and adjust accordingly.
Choledyl SA (oxtriphylline) is a sustained-release theophylline salt. Monitor serum theophylline levels (target 5-15 mcg/m L). Avoid in active peptic ulcer disease and seizure disorders. Cigarette smoking induces metabolism, requiring dose adjustments. Use with caution in patients with hepatic impairment, cardiac disease, or hypothyroidism.
AEROLATE SR contains theophylline; narrow therapeutic index (10-20 mcg/m L). Monitor serum levels, especially with CYP1A2 inhibitors (e.g., ciprofloxacin, fluvoxamine) or inducers (e.g., carbamazepine, phenytoin). SR formulation avoids peak-trough fluctuations; do not crush or chew. Caution in heart failure, hepatic impairment, and elderly.
Take exactly as prescribed; do not crush or chew the sustained-release tablets.,Avoid excessive consumption of caffeine-containing foods and beverages (coffee, tea, cola, chocolate) as they may increase side effects.,Notify your doctor if you experience nausea, vomiting, insomnia, rapid heart rate, or seizures.,Do not stop taking abruptly; dose tapering may be needed.,Inform your doctor if you smoke or stop smoking, as dose adjustments may be required.
Take exactly as prescribed; do not crush or chew the sustained-release tablet.,Do not stop suddenly; sudden withdrawal may worsen breathing.,Avoid excessive caffeine (coffee, tea, chocolate) as it may increase side effects.,Report nausea, vomiting, insomnia, palpitations, or seizures immediately.,Keep regular appointments for blood level monitoring.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CHOLEDYL SA vs AEROLATE SR, answered by our medical review team.
CHOLEDYL SA is a Bronchodilator that works by Choledyl SA (theophylline, sustained-release) is a methylxanthine that inhibits phosphodiesterase, increasing intracellular c AMP, and blocks adenosine receptors, leading to bronchodilation and anti-inflammatory effects.. AEROLATE SR is a Bronchodilator that works by AEROLATE SR is a sustained-release formulation of theophylline, a methylxanthine bronchodilator. It acts by inhibiting phosphodiesterase (PDE) isoenzymes, leading to increased intracellular cyclic AMP (c AMP) levels. This results in relaxation of bronchial smooth muscle and suppression of the response of airways to stimuli. Theophylline also has anti-inflammatory effects, including inhibition of late-phase allergen-induced responses and reduction of eosinophil infiltration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CHOLEDYL SA and AEROLATE SR depend on the specific clinical indication. These are both Bronchodilator agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CHOLEDYL SA is: 400 mg orally every 12 hours (sustained-release); maximum 800 mg every 12 hours.. The standard adult dose of AEROLATE SR is: 400-800 mcg inhaled twice daily. For acute bronchospasm, 200-400 mcg as needed.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CHOLEDYL SA and AEROLATE SR in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CHOLEDYL SA is classified as Category C. FDA Pregnancy Category C. No adequate studies in pregnant women. In animal studies, theophylline (active metabolite) caused fetal toxicity at high doses. First trimester: risk unkn. AEROLATE SR is classified as Category C. Pregnancy Category C. In first trimester: insufficient human data; animal studies show adverse effects at high doses. Second and third trimesters: may cause fetal tachycardia, hypo. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.